Literature DB >> 30393144

Parkinsonian GM2 synthase knockout mice lacking mature gangliosides develop urinary dysfunction and neurogenic bladder.

Carolina Gil-Tommee1, Guadalupe Vidal-Martinez1, C Annette Reyes1, Javier Vargas-Medrano1, Gloria V Herrera1, Silver M Martin1, Stephanie A Chaparro1, Ruth G Perez2.   

Abstract

Parkinson's disease is a neurodegenerative disorder that reduces a patients' quality of life by the relentless progression of motor and non-motor symptoms. Among the non-motor symptoms is a condition called neurogenic bladder that is associated with detrusor muscle underactivity or overactivity occurring from neurologic damage. In Parkinson's disease, Lewy-body-like protein aggregation inside neurons typically contributes to pathology. This is associated with dopaminergic neuron loss in substantia nigra pars compacta (SNc) and in ventral tegmental area (VTA), both of which play a role in micturition. GM1 gangliosides are mature glycosphingolipids that enhance normal myelination and are reduced in Parkinson's brain. To explore the role of mature gangliosides in vivo, we obtained GM2 Synthase knockout (KO) mice, which develop parkinsonian pathology including a loss of SNc dopaminergic neurons, which we reconfirmed. However, bladder function and innervation have never been assessed in this model. We compared GM2 Synthase KO and wild type (WT) littermates' urination patterns from 9 to 19 months of age by counting small and large void spots produced during 1 h tests. Because male and female mice had different patterns, we evaluated data by sex and genotype. Small void spots were significantly increased in 12-16 month GM2 Synthase KO females, consistent with overactive bladder. Similarly, at 9-12 month GM2 KO males tended to have more small void spots than WT males. As GM2 Synthase KO mice aged, both females and males had fewer small and large void spots, consistent with detrusor muscle underactivity. Ultrasounds confirmed bladder enlargement in GM2 Synthase KO mice compared to WT mice. Tyrosine hydroxylase (TH) immunohistochemistry revealed significant dopaminergic loss in GM2 Synthase KO VTA and SNc, and a trend toward TH loss in the GM2 KO periaqueductal gray (PAG) micturition centers. Levels of the nerve growth factor precursor, proNGF, were significantly increased in GM2 Synthase KO bladders and transmission electron micrographs showed atypical myelination of pelvic ganglion innervation in GM2 Synthase KO bladders. Cumulatively, our findings provide the first evidence that mature ganglioside loss affects micturition center TH neurons as well as proNGF dysregulation and abnormal innervation of the bladder. Thus, identifying therapies that will counteract these effects should be beneficial for those suffering from Parkinson's disease and related disorders.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30393144      PMCID: PMC6319267          DOI: 10.1016/j.expneurol.2018.10.014

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  76 in total

1.  Questionnaire-based assessment of bladder dysfunction in patients with mild to moderate Parkinson's disease.

Authors:  G E Lemack; R B Dewey; C G Roehrborn; P E O'Suilleabhain; P E Zimmern
Journal:  Urology       Date:  2000-08-01       Impact factor: 2.649

2.  Mice lacking complex gangliosides develop Wallerian degeneration and myelination defects.

Authors:  K A Sheikh; J Sun; Y Liu; H Kawai; T O Crawford; R L Proia; J W Griffin; R L Schnaar
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

3.  Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  J Neuropathol Exp Neurol       Date:  2008-05       Impact factor: 3.685

4.  The Vulnerable Ventral Tegmental Area in Parkinson's Disease.

Authors:  Stephanie L Alberico; Martin D Cassell; Nandakumar S Narayanan
Journal:  Basal Ganglia       Date:  2015-08-01

5.  Voiding pattern analysis as a surrogate for cystometric evaluation in uroplakin II knockout mice.

Authors:  Steve J Hodges; Ge Zhou; Fang-Ming Deng; Tamer Aboushwareb; Chanda Turner; Karl-Erik Andersson; Pete Santago; Doug Case; Tung-Tien Sun; George J Christ
Journal:  J Urol       Date:  2008-03-19       Impact factor: 7.450

Review 6.  Mechanisms of Disease: the role of nerve growth factor in the pathophysiology of bladder disorders.

Authors:  William D Steers; Jeremy B Tuttle
Journal:  Nat Clin Pract Urol       Date:  2006-02

7.  Parkinson's disease: improved function with GM1 ganglioside treatment in a randomized placebo-controlled study.

Authors:  J S Schneider; D P Roeltgen; E L Mancall; J Chapas-Crilly; D S Rothblat; G T Tatarian
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

8.  Non-motor parkinsonian pathology in aging A53T α-synuclein mice is associated with progressive synucleinopathy and altered enzymatic function.

Authors:  Kaitlin F Farrell; Sesha Krishnamachari; Ernesto Villanueva; Haiyan Lou; Tshianda N M Alerte; Eloise Peet; Robert E Drolet; Ruth G Perez
Journal:  J Neurochem       Date:  2013-11-20       Impact factor: 5.372

9.  ProNGF, but Not NGF, Switches from Neurotrophic to Apoptotic Activity in Response to Reductions in TrkA Receptor Levels.

Authors:  Maria S Ioannou; Margaret Fahnestock
Journal:  Int J Mol Sci       Date:  2017-03-09       Impact factor: 5.923

10.  Role of proNGF/p75 signaling in bladder dysfunction after spinal cord injury.

Authors:  Jae Cheon Ryu; Katharine Tooke; Susan E Malley; Anastasia Soulas; Tirzah Weiss; Nisha Ganesh; Nabila Saidi; Stephanie Daugherty; Uri Saragovi; Youko Ikeda; Irina Zabbarova; Anthony J Kanai; Mitsuharu Yoshiyama; H Francis Farhadi; William C de Groat; Margaret A Vizzard; Sung Ok Yoon
Journal:  J Clin Invest       Date:  2018-03-26       Impact factor: 14.808

View more
  5 in total

1.  FTY720 Improves Behavior, Increases Brain Derived Neurotrophic Factor Levels and Reduces α-Synuclein Pathology in Parkinsonian GM2+/- Mice.

Authors:  Guadalupe Vidal-Martinez; Katherine Najera; Julie D Miranda; Carolina Gil-Tommee; Barbara Yang; Javier Vargas-Medrano; Valeria Diaz-Pacheco; Ruth G Perez
Journal:  Neuroscience       Date:  2019-05-23       Impact factor: 3.590

2.  Functional Impairment of the Nervous System with Glycolipid Deficiencies.

Authors:  Yutaka Itokazu; Takahiro Fuchigami; Robert K Yu
Journal:  Adv Neurobiol       Date:  2023

Review 3.  GM1 Ganglioside Is A Key Factor in Maintaining the Mammalian Neuronal Functions Avoiding Neurodegeneration.

Authors:  Elena Chiricozzi; Giulia Lunghi; Erika Di Biase; Maria Fazzari; Sandro Sonnino; Laura Mauri
Journal:  Int J Mol Sci       Date:  2020-01-29       Impact factor: 5.923

Review 4.  Animal Model for Lower Urinary Tract Dysfunction in Parkinson's Disease.

Authors:  Takeya Kitta; Mifuka Ouchi; Hiroki Chiba; Madoka Higuchi; Mio Togo; Yui Abe-Takahashi; Naohisa Kusakabe; Nobuo Shinohara
Journal:  Int J Mol Sci       Date:  2020-09-07       Impact factor: 5.923

Review 5.  Gangliosides and the Treatment of Neurodegenerative Diseases: A Long Italian Tradition.

Authors:  Maria Fazzari; Giulia Lunghi; Elena Chiricozzi; Laura Mauri; Sandro Sonnino
Journal:  Biomedicines       Date:  2022-02-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.